uniQure N.V. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that uniQure N.V. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $13.11M | Mar 14, 2018 |
| FY2017 | Dec 31, 2016 | $25.10M | Mar 14, 2018 |
| FY2017 | Dec 31, 2015 | $10.58M | Mar 14, 2018 |
| FY2016 | Dec 31, 2014 | $6.14M | Mar 15, 2017 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($198.97M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | ($239.56M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | ($308.48M) | Mar 2, 2026 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($185.35M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | ($184.29M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | ($282.87M) | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | ($143.16M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $310.62M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | ($125.43M) | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | ($121.14M) | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | ($88.23M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | ($71.34M) | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | ($71.95M) | Feb 28, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $140.67M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $143.78M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $214.86M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $197.59M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $143.55M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $122.40M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $94.74M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $74.81M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $72.17M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $72.51M | Feb 28, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $65.46M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $52.66M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $74.59M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $55.06M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $56.29M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $42.58M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $33.54M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $25.31M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $24.64M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $26.00M | Feb 28, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($177.96M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | ($182.73M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | ($145.93M) | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | ($145.06M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $287.96M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | ($134.83M) | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | ($98.68M) | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | ($76.04M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | ($64.27M) | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | ($72.19M) | Feb 28, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $439.0K | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $3.37M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $7.15M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $17.69M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $17.44M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $7.27M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $5.65M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $2.38M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $4.46M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $15.29M | Feb 28, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $824.91M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $556.54M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $831.69M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $704.96M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $809.18M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $340.40M | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $448.63M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $273.91M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $209.64M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $190.27M | Mar 14, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $626.01M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $563.29M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $624.02M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $228.96M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $213.40M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $96.49M | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $125.57M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $94.30M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $120.29M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $126.63M | Mar 14, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $198.90M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | ($6.75M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $207.67M | Mar 2, 2026 |
| FY2025 | Dec 31, 2022 | $476.01M | Mar 2, 2026 |
| FY2024 | Dec 31, 2021 | $595.78M | Feb 27, 2025 |
| FY2023 | Dec 31, 2020 | $243.91M | Feb 28, 2024 |
| FY2022 | Dec 31, 2019 | $323.06M | Feb 27, 2023 |
| FY2021 | Dec 31, 2018 | $179.61M | Feb 25, 2022 |
| FY2020 | Dec 31, 2017 | $89.36M | Mar 1, 2021 |
| FY2019 | Dec 31, 2016 | $63.63M | Mar 2, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $25.36M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $22.41M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $26.38M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $25.58M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $27.63M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $542.0K | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $496.0K | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $506.0K | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $530.0K | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $465.0K | Mar 14, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.33B) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | ($1.13B) | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | ($890.41M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($581.93M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | ($455.14M) | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | ($784.73M) | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | ($659.71M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | ($535.51M) | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | ($475.32M) | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | ($396.06M) | Mar 14, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $80.24M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $158.93M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $241.36M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $228.01M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $556.26M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $244.93M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $377.79M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $234.90M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $159.37M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $132.50M | Feb 28, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $71.92M | Mar 2, 2026 |
| FY2024 | Dec 31, 2024 | $66.02M | Feb 27, 2025 |
| FY2023 | Dec 31, 2023 | $147.57M | Feb 28, 2024 |
| FY2022 | Dec 31, 2022 | $144.49M | Feb 27, 2023 |
| FY2021 | Dec 31, 2021 | $135.59M | Feb 25, 2022 |
| FY2020 | Dec 31, 2020 | $42.41M | Mar 1, 2021 |
| FY2019 | Dec 31, 2019 | $46.53M | Mar 2, 2020 |
| FY2018 | Dec 31, 2018 | $48.18M | Feb 28, 2019 |
| FY2017 | Dec 31, 2017 | $23.96M | Mar 14, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (3) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | (4) | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | (6) | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | (2) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | 7 | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | (2) | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | (3) | Feb 25, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (3) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | (4) | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | (6) | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | (2) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | 7 | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | (2) | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | (3) | Feb 25, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 62.34M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | 48.99M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | 47.83M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | 46.97M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | 46.30M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | 44.78M | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | 43.71M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | 37.35M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | 31.34M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | 25.26M | Mar 14, 2018 |